COMPANY PROFILE / SPACE INDUSTRY
Varda Space Industries
It makes things in orbit and brings them home in its own capsules, flying both government tests and drug-crystallisation trials
Varda is not a rocket company. It builds and flies small capsules that bring things back from space (we found no rocket of its own in the company's material). A Varda spacecraft circles in low Earth orbit, a few hundred kilometres up, where onboard equipment processes materials. At the end, only the capsule drops into the atmosphere and lands on the ground. According to the company's website, its spacecraft belong to the "W-Series" and are numbered W-1 to W-9. This profile relies only on the company itself, the U.S. Federal Aviation Administration (FAA) and NASA, and sets out what Varda flies, how much of it has already happened, and what is still a plan. Note that this article does not discuss the effects of any drug made in microgravity.
- Varda in 30 seconds, and where it stands in the space industry
- The logo and how the name is written
- Where the company sits in the space industry
- Scale of the company
- Resources committed to space
- What it has done so far
- What comes next
- What the company is aiming for in space
- Map of partnerships in the space industry
- Technology, products and services
- The risks this company carries
- Glossary, references and claim-to-source audit
1. Varda in 30 seconds, and where it stands in the space industry
(makes in orbit, returns to Earth)Launches as a rideshare customer; no rocket of its own is mentioned
(reentry capsule plus satellite bus)Built and operated by the company itself
vehicle operator licenceMultiple reentries until 2029 (FAA, 18 June 2025)
Companies in the space industry fall into four groups: those that carry things up by rocket, those that go to the Moon or a space station, those that operate or build in orbit, and those that make parts and systems (Figure 1 in chapter 3). Varda belongs to the third group, and what sets it apart is that it builds the capsule that comes back Sourced. It launches on SpaceX rideshare flights (flights on which one rocket carries many small satellites), and we found no rocket of its own in its releases. Instead it concentrates on building the spacecraft, the heat shield and the operations in house, and on the part that returns to the ground. The same capsule is used for government hypersonic tests (flight at more than five times the speed of sound) and for crystal-growing trials for medicines, which is unusual among space companies.
2. The logo and how the name is written
A note on names: the legal entity is Varda Space Industries, Inc., usually shortened to "Varda". "W-Series" is the name of the spacecraft family, and individual craft are called W-1, W-2 and so on. The SEC database also lists a separate entity called "Varda Space Industries a Series of CGF2021 LLC". It appears to be an investor-side vehicle, and this article is about the company itself (Varda Space Industries, Inc.) Not yet confirmed.
Official site: https://www.varda.com/ (the logo is the mark and wordmark taken from the header of the official site)3. Where the company sits in the space industry
4. Scale of the company
Varda is not listed, and it does not publish financial statements such as revenue or profit. What we could confirm is the funding the company has announced itself, plus scattered statements about sites and staff (checked on 17 October 2026) Sourced.
| Item | What we found | Type |
|---|---|---|
| Founding and founders | Founded in January 2021 by Will Bruey and Delian Asparouhov (company's account) | Sourced |
| Sites | Headquarters and production site in El Segundo, California (building, integrating and testing spacecraft, equipment and materials). Offices in Washington, D.C. and Huntsville, Alabama | Sourced |
| Employees | "More than 90" in an April 2024 announcement. We could not find a current figure | Sourced |
| Revenue and profit | Not disclosed | Not disclosed |
| Listing | Not listed. The SEC filing index shows three Form D notices (fundraising notifications) only: January and September 2021 and January 2022 | Sourced |
| Funding (company announcements) | Announced | Amount raised | Cumulative total stated | Led by |
|---|---|---|---|---|
| Series B | 5 April 2024 | US$ 90 million | US$ 145 million | Caffeinated Capital |
| Series C | 10 July 2025 | US$ 187 million | US$ 329 million | Natural Capital, Shrug Capital |
| Series D | 30 September 2026 | US$ 251 million | US$ 598 million | Lux Capital, Natural Capital |
The announced cumulative totals do not equal the sums of the individual rounds. From Series B to C, 145 + 187 = 332, against a stated total of 329. From C to D, 329 + 251 = 580, against 598 Our calculation. The published material does not explain the gaps. This article reports the company's figures as stated and does not adjust them. The company's official announcements also give no valuation for Series D. Press reports quote a number, but this article does not use figures that rest on press reports alone.
5. Resources committed to space
Space is Varda's whole business. The table below shows how far official material confirms its people, money, outside investments and contracts with public bodies (checked on 17 October 2026).
| Type of resource | What we found | Type |
|---|---|---|
| People and sites | A design, production and test site in El Segundo, plus a mission control facility (described as "newly expanded" in October 2026). More than 90 employees in April 2024. We could not find a current figure | Sourced |
| Money (raised) | Cumulative US$598 million (company announcement, 30 September 2026). The breakdown of R&D spending and capital expenditure is not disclosed | Sourced |
| Money (facilities) | In July 2025 the company said it had opened a new laboratory of about 10,000 square feet (about 930 square metres) in El Segundo. It also has a ground-based hypergravity (stronger-than-Earth gravity) crystallisation facility | Sourced |
| Outside investments, acquisitions, joint ventures, divestments | None mentioned in official material | Could not confirm |
| Public bodies: U.S. Air Force Research Laboratory (AFRL) | Funds payloads on several missions under its Prometheus programme. In January 2025 Varda announced an IDIQ flight-services contract (a contract form that lets the buyer order without fixing quantities in advance) running to 2028. The contract value is not disclosed | Sourced |
| Public bodies: NASA | Licensed the C-PICA heat-shield technology to Varda, and gave it a 2023 Tipping Point award (a technology-demonstration grant) for C-PICA production and flight testing. W-6 carried instrumented tiles for NASA's Ames Research Center | Sourced |
| Public bodies: FAA | Reentry licence (Part 450 vehicle operator licence). Details in chapter 6 | Sourced |
| Public bodies: U.S. Navy and others | W-5 carried a payload for the U.S. Navy. W-8 and W-9 carry payloads funded by government programmes (the customer and contents are not disclosed) | Sourced |
Status of the main spacecraft and missions
Every Varda spacecraft belongs to the W-Series, and each has its own launch and reentry record. The table draws on the company's mission pages and press releases (checked on 17 October 2026).
| Spacecraft | Type and payload | Launch | Reentry or end of mission | Stage |
|---|---|---|---|---|
| W-1 | Pharmaceutical processing. Grew crystals of ritonavir Form III (an HIV drug) to demonstrate the equipment (company's account) | 12 June 2023 | 21 February 2024 (landed at a Utah test range) | Completed |
| W-2 | Pharmaceutical processing, heat-shield material developed with NASA, AFRL spectrometer OSPREE. Rocket Lab satellite bus (Pioneer) | 14 January 2025 | 27 February 2025 (Koonibba Test Range, Australia) | Completed |
| W-3 | Inertial measurement unit (navigation sensor) from AFRL and ISSI | 14 March 2025 | 13 or 14 May 2025 (sources differ; Koonibba Test Range) | Completed |
| W-4 | First in-house satellite bus and heat shield. Solution-based crystallisation module (a proprietary molecule) | 23 June 2025 | Final deorbit manoeuvre on 10 May 2026 (we found no mention of recovering the capsule on the ground) | Completed (recovery unconfirmed) |
| W-5 | U.S. Navy payload. First craft to return to the ground with Varda's own satellite bus and heat shield | 28 November 2025 | 29 January 2026 (Koonibba Test Range) | Completed |
| W-6 | Autonomous navigation payload (Rhea Space Activity), a Sandia National Laboratories nose tile and two NASA instrumented tiles | 30 March 2026 | 18 May 2026 (Koonibba Test Range) | Completed |
| W-7 | Pharmaceutical processing mission (examining a solubility problem) | October 2026 (planned) | - | Not yet confirmed |
| W-8 | Fibre-optic heat-shield monitoring sensor from Canopy Aerospace & Defense, plus heat-shield materials funded by a government programme and AFRL | Announced as launched together with W-9 on 1 October 2026 (Transporter-18) | No reentry announcement found | In flight (the mission page still shows "scheduled") |
| W-9 | Government-funded navigation system and Syensqo heat-shield material samples | Same as W-8 | Same as W-8 | In flight (same note) |
In its announcement of 30 September 2026 the company says it has "completed six successful reentry missions" Sourced. The W-5 mission page, however, calls W-5 the "fifth mission overall and fourth reentry", and the W-4 page ends with a deorbit manoeuvre for the whole vehicle, satellite bus included. The six may be the five ground landings (W-1, W-2, W-3, W-5, W-6) plus the end of W-4, but we could not find how the company defines its count Not yet confirmed. This article lists each mission's dates and status in the table and quotes the company's own wording for the total.
Varda's capsule enters the atmosphere at more than 18,000 miles per hour (company's stated value; about 29,000 km/h Our calculation) Sourced. What protects its surface is a heat-shield material called C-PICA (Conformal Phenolic Impregnated Carbon Ablator). An "ablator" is a material that chars and wears away bit by bit, carrying heat away with it. NASA's Ames Research Center developed C-PICA, and Varda licensed it and now makes it in house. NASA has stated that W-5 was the first craft to return protected entirely by Varda-made C-PICA (29 January 2026). For how heat shields work, see our explainer on thermal protection systems.
6. What it has done so far
| When | What happened | What it means |
|---|---|---|
| January 2021 | Varda founded (company's account) | Set out to process materials in orbit and return them |
| 12 June 2023 | First spacecraft, W-1, launched | It stayed in orbit about eight months (from the launch and reentry dates) |
| 14 February 2024 | The FAA issued licence VOL 24-130 to Varda. It initially covered a single reentry of W-1 only | A date confirmed in the licence document itself |
| 21 February 2024 | W-1 landed at a Utah test range | The company describes it as the first commercial spacecraft to land on U.S. soil (company's claim) |
| 5 April 2024 | Raised US$90 million in a Series B | Cumulative US$145 million (company announcement) |
| January to May 2025 | W-2 (launched January) and W-3 (launched March) landed at the Koonibba Test Range in Australia | Extended landings beyond the U.S. W-3 followed about 11 weeks after W-2 |
| 18 June 2025 | The FAA announced it would allow multiple reentries until 2029 without a new application for each craft, within the authorised mission profile and vehicle design | The FAA's own statement. It described Varda as the first operator to use the multi-operation feature of the Part 450 rule |
| 23 June 2025 | W-4 launched, the first flight of an in-house satellite bus and heat shield | More of the spacecraft built in house |
| 10 July 2025 | Raised US$187 million in a Series C | Announced a new laboratory |
| 29 January 2026 | W-5 reentered, the first craft to return to the ground with its own satellite bus and C-PICA heat shield | NASA published the same day |
| 13 May 2026 | Announced a collaboration with United Therapeutics | A plan to process medicines over several missions (no results announced) |
| 18 May 2026 | W-6 reentered | Collected autonomous-navigation and NASA and Sandia heat-shield data (company's account) |
| 30 September 2026 | Raised US$251 million in a Series D | Cumulative US$598 million (company announcement) |
| 1 October 2026 | Announced W-8 and W-9 launched on the same rocket (Transporter-18) | The company calls it a world first for two craft launched together (company's claim) |
View original SVG, values and sources
Illustration One W-Series mission, step by step. A simplified diagram based on the company's website; sizes and scale are not to reality Sourced.
7. What comes next
(planned)A pharmaceutical processing mission, per the company's mission page
(no reentry announced)Announced on 1 October 2026. No reentry announcement as of the checking date
The company repeatedly speaks of raising the number of flights, building on the FAA's June 2025 permission for multiple reentries until 2029 Sourced. Its government page also says it expects a monthly reentry cadence by 2026, between government and commercial demand Not yet confirmed. These are company goals and expectations, separate from results. For 2026, the landings we can confirm so far are W-5 (29 January) and W-6 (18 May).
None of the following appears in official material Not yet confirmed.
When a medicine made in space might be approved or sold / the reentry dates of W-7, W-8 and W-9 / the value of the AFRL flight-services contract / revenue and profit / the current headcount / the content of the permits needed for landings outside the U.S. (we did not check Australian approvals). Figures such as "Varda's valuation" mostly come from press reports and are not used here.
8. What the company is aiming for in space
This chapter includes points the company has not stated directly. They are offered as inferences that the primary material supports, with the evidence.
| What we read from it | Primary evidence | Type |
|---|---|---|
| Its end goal is for the first product made in space to be a medicine | The 30 September 2026 announcement says the first product will be a pharmaceutical. W-7 is a pharmaceutical processing mission, and the United Therapeutics collaboration has been announced | Sourced |
| Government hypersonic tests carry much of the flight schedule for now | Many payloads on W-2 (in part), W-3, W-5, W-6, W-8 and W-9 are funded by the U.S. Air Force Research Laboratory, the Navy or government programmes. Only W-1, W-2, W-4 and W-7 are listed with a pharmaceutical processing mission type | Inference |
| It is trying to raise flight frequency through in-house integration | The CTO says owning the spacecraft, capsule and operations lets the company improve faster and fly more often, and W-4 and W-5 moved the satellite bus and heat shield in house | Inference |
| It leaves launch to others and concentrates on the return | Every launch we could confirm was a SpaceX rideshare flight (W-2, W-4 to W-6, W-8 and W-9). No rocket of its own is mentioned | Inference |
The company calls itself a "microgravity-enabled life sciences company" (October 2026 announcement). Yet in the flight record, only W-1, W-2, W-4 and W-7 are listed as pharmaceutical processing missions, while W-3, W-5, W-6, W-8 and W-9 centre on government reentry tests Sourced. The company also explains that for its government test bed, "commercial customers require low-cost reentry, leading to cost benefits for government missions". Together these suggest a division of roles: government tests build up flight numbers and operating experience, and that experience also serves the pharmaceutical flights Not yet confirmed. However, the split of government and pharmaceutical revenue is not disclosed, so outsiders cannot tell which is the larger part of the business.
9. Map of partnerships in the space industry
10. Technology, products and services
| Offering | What it is (company's account) | Type |
|---|---|---|
| W-Series (spacecraft) | A satellite bus (power, communications, attitude control, propulsion) plus a reentry capsule. Designed, built and operated in house. Used for government tests, pharmaceutical processing and research | Sourced |
| Government hypersonic test bed | The capsule enters the atmosphere at Mach 25 or more and lands by parachute. The company says the payload capacity is "over 100 W of power, tens of kilograms of internal mass and plenty of area for thermal protection material" (company's stated value) | Sourced |
| Pharmaceutical processing (crystallisation) | For small molecules and biologics, equipment heats, mixes and cools in microgravity to make crystals, which return to Earth for analysis. W-4 introduced a solution-based method | Sourced |
| Ground-based hypergravity crystallisation | Crystallisation is tried at higher-than-Earth gravity to narrow down compounds suited to microgravity (company's account) | Sourced |
| C-PICA heat shield | Licensed from NASA and made in El Segundo. Fitted to W-4 and later craft | Sourced |
| Microgravity research service | Takes outside researchers' payloads, runs automated experiments in orbit and returns them to the ground | Sourced |
The company explains that in microgravity convection (liquid moving because of temperature differences) and sedimentation (heavy particles sinking) are suppressed, so crystals tend to be more uniform in size and structure Sourced. In materials terms, on Earth the flow of liquid and the settling of particles disturb how a crystal grows. Remove those, and it becomes easier to study how a crystal grows with gravity's influence set aside. The company says its ground facility, which applies stronger gravity, is there to treat gravity as a continuous variable and so predict what will happen in microgravity. This article does not address how a medicine behaves, or how well it works, once used. For that, check the announcements of the company and its partners directly. For the basics of crystallisation, see our explainers on space manufacturing and microgravity, and on microgravity drug discovery and protein crystallisation.
11. The risks this company carries
| Risk | What it involves | Type |
|---|---|---|
| Reliance on government test flights | Most of the flight record we can confirm is government-funded payloads. Changes in government budgets or policy could affect flight numbers | Inference |
| Medicine demonstration still under way | The company says the first product made in space will be a medicine, but the timing and the target are unannounced. W-7 is still to come | Sourced |
| Limits of the licence | The FAA permission allows multiple reentries until 2029 within the authorised mission profile and vehicle design. Flights outside that scope could need a fresh review | Sourced |
| Reliance on outside launch | Every launch we could confirm (W-2, W-4 to W-6, W-8 and W-9) was a SpaceX rideshare flight, so its schedule follows the rideshare schedule | Inference |
| Differences in how results are counted | The company's statement of reentry numbers does not fully match its mission pages (chapter 5) | Sourced |
| Finances cannot be checked from outside | Revenue, costs and valuation are undisclosed, and the cumulative funding totals do not equal the sum of the rounds | Not yet confirmed |
| Gap between goals and results | Against the company's expectation of monthly reentries by 2026, the 2026 landings we can confirm are W-5 and W-6 (as of 17 October 2026) | Not yet confirmed |
12. Glossary
- Low Earth orbit (LEO)
- An orbit up to about 2,000 km above the ground. The International Space Station circles here.
- Reentry
- Coming back into the atmosphere from space. Friction with the air heats the surface intensely.
- Hypersonic
- More than five times the speed of sound. The company says its capsule exceeds Mach 25.
- Satellite bus
- The base of a satellite. It handles power, communications, attitude control and propulsion.
- Payload
- The cargo a spacecraft carries, such as experiments, sensors or material samples.
- Rideshare launch
- Several satellites share one rocket to split the cost.
- Microgravity
- An environment where gravity seems almost absent. In orbit it arises because everything is in continuous free fall.
- Ablator
- A heat-shield material that chars and wears away bit by bit, carrying heat off. C-PICA is one.
- Part 450
- The FAA's rule on licensing launches and reentries (14 CFR Part 450).
- AFRL and Prometheus
- The U.S. Air Force Research Laboratory (AFRL) and its joint test programme with commercial reentry providers.
- Tipping Point
- A NASA scheme that funds technology demonstrations close to commercial use.
- Form D
- A notice filed with the SEC after a private fundraising in the U.S. It contains no financial statements.
13. References
- Varda Space Industries Official website, home page (self-description; announcement of W-8 and W-9 launch). https://www.varda.com/
- Varda Space Industries Official website, "Our story" (founding, sites, investors). https://www.varda.com/company
- Varda Space Industries Official website, "Platform" (W-Series description, mission list, flight sequence). https://www.varda.com/platform
- Varda Space Industries Official website, "Government" (hypersonic test bed description, payload capacity, expected monthly reentry cadence). https://www.varda.com/government
- Varda Space Industries Official website, "Biopharma" (the company's account of microgravity and crystallisation, ground-based hypergravity facility, analytical methods). https://www.varda.com/biopharma
- Varda Space Industries Official website, W-1 mission page (launched 12 June 2023, reentered 21 February 2024). https://www.varda.com/mission/w-1
- Varda Space Industries Official website, W-2 mission page (launched 14 January 2025, reentered 27 February 2025). https://www.varda.com/mission/w-2
- Varda Space Industries Official website, W-3 mission page (launched 14 March 2025; the page gives the reentry date as both 13 and 14 May). https://www.varda.com/mission/w-3
- Varda Space Industries Official website, W-4 mission page (launched 23 June 2025; final deorbit manoeuvre on 10 May 2026). https://www.varda.com/mission/w-4
- Varda Space Industries Official website, W-5 mission page (launched 28 November 2025, reentered 29 January 2026). https://www.varda.com/mission/w-5
- Varda Space Industries Official website, W-6 mission page (launched 30 March 2026, reentered 18 May 2026). https://www.varda.com/mission/w-6
- Varda Space Industries Official website, W-7 mission page (October 2026, pharmaceutical processing mission). https://www.varda.com/mission/w-7
- Varda Space Industries Official website, W-8 mission page (W-8 payloads; shown as scheduled). https://www.varda.com/mission/w-8
- Varda Space Industries Official website, W-9 mission page (W-9 payloads; shown as scheduled). https://www.varda.com/mission/w-9
- Varda Space Industries (PR Newswire) Press release "Varda Announces $90 Million Series B Funding to Build Factories in Space" (5 April 2024). https://www.prnewswire.com/news-releases/varda-announces-90-million-series-b-funding-to-build-factories-in-space-302108949.html
- Varda Space Industries (PR Newswire) Press release "Varda Announces $187 Million in Series C Funding to Make Medicines in Space" (10 July 2025). https://www.prnewswire.com/news-releases/varda-announces-187-million-in-series-c-funding-to-make-medicines-in-space-302502096.html
- Varda Space Industries (PR Newswire) Press release "Varda Announces $251 Million Series D to Scale Space-Based Pharmaceutical Processing" (30 September 2026). https://www.prnewswire.com/news-releases/varda-announces-251-million-series-d-to-scale-space-based-pharmaceutical-processing-302893651.html
- Varda Space Industries (PR Newswire) Press release "Varda's Second Mission, W-2, Launches with Payloads from Air Force Research Laboratory and NASA" (14 January 2025). https://www.prnewswire.com/news-releases/vardas-second-mission-w-2-launches-with-payloads-from-air-force-research-laboratory-and-nasa-302350940.html
- Varda Space Industries (PR Newswire) Press release "Varda's W-3 Capsule Lands Successfully in South Australia" (14 May 2025). https://www.prnewswire.com/news-releases/vardas-w-3-capsule-lands-successfully-in-south-australia-302454970.html
- Varda Space Industries (PR Newswire) Press release "Varda Space Industries Launches W-4 with the FAA's First-Ever Reentry Vehicle Operator License and Debuts an In-House Satellite Bus" (23 June 2025). https://www.prnewswire.com/news-releases/varda-space-industries-launches-w-4-with-the-faas-first-ever-reentry-vehicle-operator-license-and-debuts-an-in-house-satellite-bus-302488811.html
- Varda Space Industries (PR Newswire) Press release "Varda Launches W-5, the Company's Fifth Mission and Fourth Launch of 2025" (28 November 2025). https://www.prnewswire.com/news-releases/varda-launches-w-5-the-companys-fifth-mission-and-fourth-launch-of-2025-302628304.html
- Varda Space Industries (PR Newswire) Press release "Varda Space Industries Successfully Executes W-5 Mission Reentry, Debuting Vertically Integrated Satellite Bus" (29 January 2026). https://www.prnewswire.com/news-releases/varda-space-industries-successfully-executes-w-5-mission-reentry-debuting-vertically-integrated-satellite-bus-302674203.html
- Varda Space Industries (PR Newswire) Press release "Varda Launches W-6, Expanding Hypersonic Reentry and Autonomous Navigation Capabilities" (30 March 2026). https://www.prnewswire.com/news-releases/varda-launches-w-6-expanding-hypersonic-reentry-and-autonomous-navigation-capabilities-302728592.html
- Varda Space Industries (PR Newswire) Press release "Varda Space Industries Successfully Reenters W-6, Validating Autonomous Navigation and Advanced Thermal Protection Systems" (19 May 2026). https://www.prnewswire.com/news-releases/varda-space-industries-successfully-reenters-w-6-validating-autonomous-navigation-and-advanced-thermal-protection-systems-302775804.html
- Varda Space Industries (PR Newswire) Press release "Varda Space Industries and United Therapeutics Collaborate to Advance Microgravity-Enabled Treatments for Rare Pulmonary Disease" (13 May 2026). https://www.prnewswire.com/news-releases/varda-space-industries-and-united-therapeutics-collaborate-to-advance-microgravity-enabled-treatments-for-rare-pulmonary-disease-302770786.html
- Varda Space Industries (PR Newswire) Press release "Varda Space Industries Launches Two Vehicles to Orbit at the Same Time" (1 October 2026). https://www.prnewswire.com/news-releases/varda-space-industries-launches-two-vehicles-to-orbit-at-the-same-time-302896502.html
- Federal Aviation Administration (FAA) Commercial Space Transportation License No. VOL 24-130, Varda Space Industries, Inc. (issued 14 February 2024). https://www.faa.gov/media/75536
- Federal Aviation Administration (FAA) Finding of No Significant Impact and Record of Decision for Proposed Issuance of a Vehicle Operator License to Varda (environmental decision document, February 2024). https://www.faa.gov/media/75516
- Federal Aviation Administration (FAA) FAA General Statements, item "FAA Authorizes Varda Space for Multiple Reentry Missions under Part 450 Rule" (18 June 2025). https://www.faa.gov/newsroom/statements/general-statements
- National Aeronautics and Space Administration (NASA) "NASA Heat Shield Technology Enables Space Industry Growth" (W-5 reentry and C-PICA; 29 January 2026, last updated 22 June 2026). https://www.nasa.gov/directorates/stmd/nasa-heat-shield-technology-enables-space-industry-growth/
- U.S. SEC EDGAR filing index for Varda Space Industries, Inc. (CIK 0001839597): three Form D filings only (January and September 2021, January 2022). https://data.sec.gov/submissions/CIK0001839597.json
14. Claim-to-source audit
Last updated: 17 October 2026 / Troy Technical
The facts in this article rest on Varda Space Industries' website and official press releases, FAA licensing documents and statements, NASA's announcement and the SEC filing index. Market-research estimates and figures that rest on press reports alone (including valuations) are not used. This field moves quickly, so the status of spacecraft and missions is as of the checking date (17 October 2026). Passages marked "Inference" are our own reading of the primary material and are not statements by the company. The article does not address the effects or efficacy of drugs made in microgravity, and is not medical advice.